Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05264051 · ClinicalTrials.gov registry record
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
A clinical trial of Liver Diseases, sponsored by University of Chicago.
- Recruiting
- Registry status
- 1,200
- Enrollment target
- 1
- Study location
NCT05264051: Recruiting study of Liver Diseases, sponsored by University of Chicago.
NCT05264051 is a study of Liver Diseases that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 1,200 participants, below the 61,122-participant average among 33 other Liver Diseases trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05264051, a study of Liver Diseases, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
Primary Outcome
Death prior to liver transplant or delisting from enrollment in the study
Conditions Studied
Study Locations (1)
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2022-04-18 |
| Est. Completion | 2027-03-01 |
What NCT05264051 shows while recruiting
NCT05264051 is an observational study that tracks outcomes without assigning an intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, below the 61,122-participant average among 33 other Liver Diseases trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Liver Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT05264051 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05264051 about?
NCT05264051 is a clinical study titled "MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease". The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
What is the current status of trial NCT05264051?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2022-04-18. Estimated completion is 2027-03-01.
What conditions does trial NCT05264051 study?
This clinical trial studies the following conditions: Liver Diseases.
Who is sponsoring clinical trial NCT05264051?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05264051 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05264051's enrollment target sits among peer trials
1,200 6th of 33 higher than 28 of 33 other Liver Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
RECRUITING · NA
-
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
RECRUITING · NA
-
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
RECRUITING · Phase 1
-
Genetic Collection Protocol
RECRUITING
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
RECRUITING · NA
-
A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI